UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000057029
Receipt number R000065185
Scientific Title Examination of optimal patient endpoints in developing new therapeutic drugs for symptomatic bradycardia.
Date of disclosure of the study information 2025/04/01
Last modified on 2025/04/02 16:23:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Examination of optimal patient endpoints in developing new therapeutic drugs for symptomatic bradycardia.

Acronym

EXPAND-Study

Scientific Title

Examination of optimal patient endpoints in developing new therapeutic drugs for symptomatic bradycardia.

Scientific Title:Acronym

EXPAND-Study

Region

Japan


Condition

Condition

bradyarrhythmia

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate quality of life before and after novel pacemaker implantation treatment for symptomatic bradyarrhythmia using multiple quality of life assessment indices with established evidence for heart failure.

Basic objectives2

Others

Basic objectives -Others

The various symptoms of symptomatic bradyarrhythmia, the diversity of patient backgrounds such as age and disease, and the variability of various QOL indices will be extracted, leading to the creation of optimal QOL evaluation indices for a population of patients who are expected to be included in future clinical trials for symptomatic bradyarrhythmias.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Changes in various quality of life indices before and after pacemaker implantation.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

A

Key exclusion criteria

A

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Yoshihiro
Middle name
Last name Asano

Organization

National Cerebral and Cardiovascular Center

Division name

Genome Medicine Support Department

Zip code

564-8565

Address

6-1 Kishibe Shinmachi, Suita City, Osaka, Japan

TEL

06-6170-1070

Email

asano.yoshihiro@ncvc.go.jp


Public contact

Name of contact person

1st name Yoshihiro
Middle name
Last name Asano

Organization

National Cerebral and Cardiovascular Center

Division name

Genome Medicine Support Department

Zip code

564-8565

Address

6-1 Kishibe Shinmachi, Suita City, Osaka, Japan

TEL

06-6170-1070

Homepage URL


Email

asano.yoshihiro@ncvc.go.jp


Sponsor or person

Institute

National Cerebral and Cardiovascular Center Hospital

Institute

Department

Personal name



Funding Source

Organization

Japan Agent for Medical Research and Development

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Osaka University Hospital Ethics Application Committee

Address

2-2 Yamadaoka, Suita City, Osaka, Japan

Tel

06-6210-8296

Email

rinri@hp-crc.med.osaka-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2024 Year 12 Month 05 Day

Date of IRB


Anticipated trial start date

2025 Year 05 Month 01 Day

Last follow-up date

2026 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

NONE


Management information

Registered date

2025 Year 02 Month 14 Day

Last modified on

2025 Year 04 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065185